medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 2

<< Back Next >>

Med Int Mex 2010; 26 (2)

Skin reactivity to coccidioidin in onco-hematological patients

Álvarez GB, Esquivel MCG, Barbachano RE, Belmontes UO, Martínez MJA, Galindo OJA

Language: Spanish
References: 24
Page: 95-99
PDF size: 196.94 Kb.


ABSTRACT

Background: The coccidiodin (+) prevalence in the general population is of 40 a 60 %, in endemic areas in the northeast region of Mexico was 0.04.
Objective: Determinate the prevalence of Skin reactivity to the coccidiodina in patient of oncology in treatment chemotherapy with a point of court of ›de 5 mm.
Material and Method: cross-sectional study conducted in 95 cancer patients at different stages you apply coccidiodina intracutaneous 0.1 mL in dilution 1:100, to 95 subject cancer chemotherapy treatments, radiotherapy and immunotherapy. And their reading was of the 48-72 following hours.
Results: The age average 95 fellows was of 47 years +-16.20, minimum of 18, maxim of 78, range 60. Of them 54.7% (52) they were; masculine, 45.3% (43) to the feminine. The observed prevalence was of 20% with intervals of confidence IC 95% (17.68 - 22.31), standard error of .6015 and c2 =31.842 G.L. = 1 p ‹ .001
Conclusions: The positive coccidiodina in patient with cancer in alone treatment indicates infection for c. previous immitis and activity of the cellular immunity.


REFERENCES

  1. Institute of Medicine. Clearing the air: Asthma and indoor air exposures. Washington: National Academy Press, 2000;p:158- 175.

  2. Center for Disease Control and Prevention. State of the science on molds and human health, July 18, 2002, available at: http:www.cdc.gov/nceh/airpollution/images/moldcast.pdf

  3. Dismukes WE. Introduction to the mycosis. In: Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. 21st rev ed. Philadelphia: WB Saunders, 2000;p:1858-1860.

  4. González Cejudo MN. Infecciones micóticas graves. Capitulo

  5. En: Arredondo JL, Figueroa-Damián. Temas actuales en Infectologia. 1a ed. México: Intersistemas, 2000;pp:83- 93.

  6. Milne C, Sande MA. Coccidiodes. Chapter 72. In: Wilson WR, Sande MA. Diagnosis & treatment Infectious Disease. New York: Lange Medical Book/-McGraw-Hill, 2001;p:731- 734.

  7. Woodruff III WW, Buckley III E, Gallis HA, Cohn JR, Wheat RW. Reactivity to spherule-derived Coccidiodin in the south eastern United States. Infection and Immunity 1984;43(3): 860-869.

  8. Padua y Gabriel A, Martinez-Ordaz VA, Velasco-Rodriguez VM, Lazo-Saenz JG, Cicero R. Prevalence of Skin Reactivity Coccidiodin and Associated Risk Factors in Subjects Living in Northern City of Mexico. Archives of Medical Research 1999;30:388-392.

  9. Gonzáles-Ochoa A. La importancia médica de la coccidiodomicosis en la frontera entre México y Estados Unidos de América. Salud Pública Mex 1968;10:319-326.

  10. Verduzco E, Portales A, Mondjardin S, y col. Características clínicas y epidemiológicas de la coccidiodomicosis en la Comarca Lagunera. Salud Pública 1965;7:397-403.

  11. Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clinical Microbiology Reviews 1990;3:247-68.

  12. Vargas de Camino N, Vargas Montiel H, Molero M. Inmunodiagnóstico de las micosis sistémicas. Dermatología Venezolana 1995;33(2):65-82.

  13. Gotzche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. The Cochrane library, volume (4) 2006 http://gateway. ut.ovid.com/gwl/ovidweb.cgi ingreso 15/01/2007; p:1-42.

  14. Stevens DA. Coccidioidomycosis. N Engl J 1995;332(16):1077- 1081.

  15. Barbee RA, Hicks MJ. Clinical usefulness of lymphocyte transformation in patients with coccidioidomycosis. Chest 1988;93(5)1003-1007.

  16. Velasco-Rodríguez VM, et al. Muestreo y tamaño de muestra. Una guía práctica para personal de salud que realiza investigación. Libro.net 2003.

  17. Dodge RR, Lebowitz MD, Barbee R, Burrows B. Estimates of C. immitis by skin test reactivity in endemic community. Am J Publ Health 1985; 75; 863-5.

  18. Sarosi GA, Catanzaro A, Daniel TM, Davies SF. Clinical usefulness of skin testing in histoplasmosis, coccidioidomycosis and blastomycosis. Am Rev Resp Dis 1988:1081-2.

  19. Dawson-Saunders, Trapp RG. Bioestadística médica. 2ª ed. México: Manual Moderno, 1997;pp: 259.

  20. Velasco-Rodríguez VM, Martínez-Ordaz VA, Padua y Gabriel A, Lazo-Sáenz JG, Cicero-Sabido R. Utilidad de la prueba cutánea a la coccidiodina en personas con diabetes mellitus tipo 2 en una zona endémica. Rev Invest Clin 2001; 53(3):223- 227.

  21. Esquivel-Molina CG, Velasco-Rodríguez VM, Guzmán-Solano S, Luna-Burciaga JD, Borbón-Rosas R, Jacobo-Ávila A. Infección latente tuberculosa en pacientes con artritis reumatoide. Med Int Mex 2006;22:3-9.

  22. Abbas AK. Inmunidad frente a los tumores. Capitulo. 17. En: Abbas AK, Lichtman AH. Inmunologia Celular y Molecular. 5a ed. Barcelona: Elsevier, 2004;p:391-410.

  23. Singh VR, Smith DK, Lawrence J, Nelly PC, Thomas AR, Spitz B, Sarosi GA. Coccidiodomicosis in patients infected with human immunodeficiency virus: review of 91 cases at the single institution. Clin Infec Disease 1996; 23: 563- 568.

  24. Neil M. Resnik, MD. Cancer. Capitulo 4. En; Tierney LM, McPhee SJ, Papadakis MA. Diagnostico Clínico y Tratamiento. 36ª ed. México: Manual Moderno, 2001;p:71- 108.




2020     |     www.medigraphic.com